China NMPA Answers Questions about CSAR Implementation

Jan 21, 2021

Hedy He

There is no pre-market review on notification documents.

Efficacy claims will be managed through social supervision.

Cosmetic online sales will become one of the regulatory focuses.

On Jan. 14, 2021, China National Medical Products Administration (NMPA) held a news briefing on Cosmetic Supervision and Administration Regulation (CSAR) implementation. ^[1] During the briefing, the following three officials answered several questions about CSAR implementation.

Liubin Qi, Deputy Director of the Department of Cosmetics Regulation of NMPA;
Qingbin Lin, Researcher of the Division of Supervision I; and
Yunfeng Li, Division Chief of the Division of Supervision II.

Source: NMPA Official Website

ChemLinked summarizes the key points as follows.

1. No Pre-market Review on Notification Documents

Please Log in or Sign up (FREE) to read the full content.

We provide full-scale Chinese cosmetic market entry services (including cosmetic registering & filing, regulatory consultation, customized training, market research, branding strategy). Please contact us to discuss how we can help you by cosmetic@chemlinked.com

Hedy He
ChemLinked Regulatory Analyst

FOLLOW

Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com